Synonym
Lu 19005; Lu-19005; Lu19005; Lu-19-005; Lu 19-005; Lu19-005;
IUPAC/Chemical Name
(1S,3R)-3-(3,4-dichlorophenyl)-N-methyl-2,3-dihydro-1H-inden-1-amine
InChi Key
SVFXPTLYMIXFRX-CJNGLKHVSA-N
InChi Code
InChI=1S/C16H15Cl2N/c1-19-16-9-13(11-4-2-3-5-12(11)16)10-6-7-14(17)15(18)8-10/h2-8,13,16,19H,9H2,1H3/t13-,16+/m1/s1
SMILES Code
CN[C@H]1C[C@H](C2=CC=C(Cl)C(Cl)=C2)C3=C1C=CC=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
292.20
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Rosenzweig-Lipson S, Bergman J, Spealman RD, Madras BK. Stereoselective behavioral effects of Lu 19-005 in monkeys: relation to binding at cocaine recognition sites. Psychopharmacology (Berl). 1992;107(2-3):186-94. PubMed PMID: 1377395.
2: Hyttel J, Larsen JJ. Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline, and serotonin. J Neurochem. 1985 May;44(5):1615-22. PubMed PMID: 2580950.
3: Arnt J, Christensen AV, Hyttel J. Pharmacology in vivo of the phenylindan derivative, Lu 19-005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1985 Apr;329(2):101-7. PubMed PMID: 2409454.
4: Nowak G, Arnt J, Hyttel J, Svendsen O. Down-regulation of dopamine D-2, 5-HT2 receptors and beta-adrenoceptors in rat brain after prolonged treatment with a new potential antidepressant, Lu 19-005. J Neural Transm. 1985;64(3-4):227-38. PubMed PMID: 2418155.
5: Hurd YL, Ungerstedt U. Ca2+ dependence of the amphetamine, nomifensine, and Lu 19-005 effect on in vivo dopamine transmission. Eur J Pharmacol. 1989 Jul 18;166(2):261-9. PubMed PMID: 2477260.
6: Hurd YL, Ungerstedt U. In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen. Eur J Pharmacol. 1989 Jul 18;166(2):251-60. PubMed PMID: 2477259.
7: Stengård K. Effect of toluene inhalation on extracellular striatal acetylcholine release studied with microdialysis. Pharmacol Toxicol. 1994 Aug;75(2):115-8. PubMed PMID: 7526361.
8: Rothman RB, Partilla JS, Baumann MH, Dersch CM, Carroll FI, Rice KC. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse. 2000 Mar 1;35(3):222-7. PubMed PMID: 10657029.
9: Hurd YL, Ungerstedt U. Influence of a carrier transport process on in vivo release and metabolism of dopamine: dependence on extracellular Na+. Life Sci. 1989;45(4):283-93. PubMed PMID: 2474734.
10: Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS, al-Tikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer JL, et al. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse. 1993 Apr;13(4):295-309. PubMed PMID: 7683143.
11: Negus SS, Brandt MR, Mello NK. Effects of the long-acting monoamine reuptake inhibitor indatraline on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther. 1999 Oct;291(1):60-9. PubMed PMID: 10490887.
